A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
Copyright © 2020 Elsevier Ltd. All rights reserved..
Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:250 |
|---|---|
| Enthalten in: |
Carbohydrate polymers - 250(2020) vom: 15. Dez., Seite 116800 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rasul, Ruhisy Mohd [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9012-76-4 |
|---|
| Anmerkungen: |
Date Completed 21.10.2020 Date Revised 03.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carbpol.2020.116800 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316194654 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316194654 | ||
| 003 | DE-627 | ||
| 005 | 20231225160545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carbpol.2020.116800 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316194654 | ||
| 035 | |a (NLM)33049807 | ||
| 035 | |a (PII)S0144-8617(20)30973-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rasul, Ruhisy Mohd |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2020 | ||
| 500 | |a Date Revised 03.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Chitosan | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Nanoparticle | |
| 650 | 4 | |a Pulmonary drug delivery | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 700 | 1 | |a Tamilarasi Muniandy, M |e verfasserin |4 aut | |
| 700 | 1 | |a Zakaria, Zabliza |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Kifayatullah |e verfasserin |4 aut | |
| 700 | 1 | |a Chee, Chin Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Dabbagh, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Noorsaadah Abd |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Tin Wui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Carbohydrate polymers |d 1994 |g 250(2020) vom: 15. Dez., Seite 116800 |w (DE-627)NLM082819491 |x 1879-1344 |7 nnns |
| 773 | 1 | 8 | |g volume:250 |g year:2020 |g day:15 |g month:12 |g pages:116800 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carbpol.2020.116800 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 250 |j 2020 |b 15 |c 12 |h 116800 | ||